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Pulmonary embolism and 3-month outcomes in
4036 patients with venous thromboembolism
and chronic obstructive pulmonary disease: data
from the RIETE registry
Laurent Bertoletti1,2,3*†, Sara Quenet1†, Silvy Laporte1,2,3, Joan Carles Sahuquillo4, Francisco Conget5,
José María Pedrajas6, Mar Martin7, Ignacio Casado8, Antonio Riera-Mestre9, Manuel Monreal10
and The RIETE Investigators
Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) have a modified clinical presentation of
venous thromboembolism (VTE) but also a worse prognosis than non-COPD patients with VTE. As it may induce
therapeutic modifications, we evaluated the influence of the initial VTE presentation on the 3-month outcomes in
COPD patients.
Methods: COPD patients included in the on-going world-wide RIETE Registry were studied. The rate of pulmonary
embolism (PE), major bleeding and death during the first 3 months in COPD patients were compared according to
their initial clinical presentation (acute PE or deep vein thrombosis (DVT)).
Results: Of the 4036 COPD patients included, 2452 (61%; 95% CI: 59.2-62.3) initially presented with PE. PE as the
first VTE recurrence occurred in 116 patients, major bleeding in 101 patients and mortality in 443 patients (Fatal PE:
first cause of death). Multivariate analysis confirmed that presenting with PE was associated with higher risk of VTE
recurrence as PE (OR, 2.04; 95% CI: 1.11-3.72) and higher risk of fatal PE (OR, 7.77; 95% CI: 2.92-15.7).
Conclusions: COPD patients presenting with PE have an increased risk for PE recurrences and fatal PE compared
with those presenting with DVT alone. More efficient therapy is needed in this subtype of patients.
Keywords: Chronic obstructive pulmonary diseases, Deep venous thrombosis, Prognosis, Pulmonary embolism,
Venous thromboembolism
Background
Chronic obstructive pulmonary disease (COPD) is a com-
mon and severe medical condition: it affects more than 10%
of people over 40 years old [1] and the World Health
Organization estimates it will become the fourth leading
cause of death in 2030 worldwide [2]. Recent data showed
that about one in every four individuals will be diagnosed
for COPD during their lifetime [3].
COPD is recognized as a moderate risk factor for another
frequent disease : venous thromboembolism (VTE), in
the same group than cancer or hormonal therapy [4].
Pulmonary embolism (PE) and deep venous thrombosis
(DVT) are the two clinical presentation forms of VTE.
DVT is two times more frequent than PE in the general
setting, whereas PE have a higher risk of death [5]. As
patients with COPD have reduced pulmonary vascular
reserve, PE is considered to be a major threat in COPD
patients, reported to be responsible of at least 10% of deaths
[6] but its evocation may be challenging, particularly during
an acute exacerbation of COPD [7-9].
We recently found that COPD patients with VTE have
a higher embolic “tropism” than non COPD patients
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[10]. The clinical presentation of VTE (say PE or DVT)
in COPD patients is modified with higher PE/DVT ratio
than non COPD patients. They also experiment higher
rates of VTE recurrences as PE, and higher rates of fatal
PE. In the general setting, these outcomes are influenced
by the initial VTE clinical presentation (say PE or DVT).
For example, patients presenting initially with DVT have
higher risk to present with DVT rather than PE in case
of recurrence. It is unclear if it remains true in COPD,
because of its higher embolic tropism. Moreover, these
worse outcomes might prompt clinicians to increase the
antithrombotic pressure, but we also found that COPD
patients experiment higher risk of bleeding than non-
COPD patients and this point should conversely prompt
clinicians to avoid exposure to an increase risk of bleeding.
Hence, we aimed to assess the association between the
clinical presentation of VTE (PE or DVT) and the risk of
3-month adverse outcomes (i.e. PE, major bleeding and
death during the follow-up) in patients with an objectively
confirmed acute symptomatic VTE and underlying COPD
from the RIETE Registry.
Materials and methods
Registry design
The RIETE registry is an ongoing, international, multicen-
ter, prospective cohort of consecutive patients with symp-
tomatic, objectively confirmed, acute VTE (DVT, PE, or
both). Patients are managed according to the clinical prac-
tice of each participating hospital center. The only exclusion
criterium is participation in a therapeutic clinical trial with
blind medication. Demographic data and comobidities such
as cancer, COPD, chronic heart failure or renal insufficiency
at the time of the index event are systematically prospect-
ively recorded by the treating physician. For this analysis,
only COPD patients were considered. At each participating
center, a registry coordinator controlled the quality of data
collection (eg, internal validity and coherence) and recorded
the data from each patient on a computer-based case report
form. Coordinators ensured that all consecutive patients
with confirmed VTE were included in the registry. In
addition, the database of each analysis was controlled. The
information was then transferred online via a secure Web
site to the Study Coordinating Centre responsible for data
management. Data quality was also monitored by members
of contract research organizations who compared the data
on medical records with the data transferred online during
periodic visits to participating hospitals. All patients pro-
vided oral or written consent to their participation in the
registry, in accordance with the requirements of the ethics
committee of each country.
Study variables and definition
For the purpose of the present study, COPD patients
were divided according to their initial VTE presentation:
PE patients defined as patients with an objectively
confirmed initial symptomatic PE (with or without DVT)
or patients who died from PE less than 8 days after their
first symptoms of PE with no evidence of PE recurrence,
and DVT patients defined as patients with an objectively
confirmed initial symptomatic DVT without symptomatic
PE. The following information was also collected:
demographic data, symptoms on presentation, types and
results of VTE diagnosis methods, risk factors for VTE,
and the 3-month outcomes. Recent immobilization is
defined as an immobilization for non-surgical reason ≥4
days in the 2-month period prior to VTE diagnosis. Recent
surgery is defined as operation in the 2 month prior to
VTE. Obesity is defined by a BMI>30 kg/m2.
Study outcomes
In the present study, the occurrence of an objectively
confirmed PE, major bleeding, fatal PE and all-cause
death were the outcomes of interest that were analyzed
during a 3-month follow-up period. In patients with acute
respiratory symptoms suggesting PE, symptomatic PE was
confirmed if it was documented objectively (positive helical
computed tomography scan, high-probability ventilation–
perfusion lung scan, positive pulmonary angiography,
visualization of thrombus in right ventricle or right atrium
on echocardiography, or intermediate-probability ventila-
tion–perfusion lung scan associated with deep-vein throm-
bosis in the lower limbs confirmed by compression
ultrasonography or contrast venography). If the patient died,
death was considered to be due to PE if this diagnosis had
been documented at autopsy, or if the patient died shortly
(less than 10 days) after objectively confirmed symptomatic
PE, and in the absence of any alternative diagnosis.
Bleeding complications were classified as ‘major’ if they
were overt and required a transfusion of 2 or more units
of bloods, were retroperitoneal, spinal or intracranial, or
were fatal.
These events were adjudicated by the RIETE registry
coordinators.
Data analysis
Differences in the distribution of characteristics between
PE patients and DVT patients were assessed using
Chi square tests for categorical variables and t test
for continuous variables. Cumulative incidence rates
of first VTE recurrence as PE, fatal PE (either the first
or subsequent VTE recurrence), all-cause death and major
bleedings were estimated using the Kaplan-Meier method
and compared between PE patients and DVT patients by
the log-rank test. Cox proportional hazards regression
models were used to examine whether initial presentation
with PE was associated with the study outcomes. Odds
ratios and 95% confidence intervals (CIs) were used to
quantify the associations.
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Data were processed and analyzed using SAS-Windows™
software (version 9.2).
Results
Between March 2001 and June 2011, 36949 consecutive
patients over 18 years with acute, symptomatic, objectively
confirmed VTE have been enrolled in RIETE. Of them,
4036 (10.9%) had COPD: 2693 patients (66.7%) were
male and 1343 female. The age of the COPD population
(mean±SD) was 72.85 ± 11.53 years. Cancer was reported
in 888 (22.0%) of COPD patients.
Initial VTE presentation
At study entry, 2452 COPD patients (61%) were
objectively diagnosed as having PE. Compared to the
1584 DVT patients, PE patients were significantly
older (patients over 75: 54.3% vs 45.9%, p<0.0001)
and were more likely female (35.6% vs 29.7%, p<0.0001).
Conversely, obesity as well as a history of VTE were less
often associated with PE at presentation (respectively
19.2% vs 22.5%, p=0.02; 15.6% vs 18.3%, p=0.02) (Table 1).
First VTE recurrence as PE during the 3-month follow-up
At 3 months, the first VTE recurrence as PE occurred in
116 patients (2.9%; 95% confidence interval (CI): 2.4-3.4)
(Figure 1). The cumulative incidence rates of first
symptomatic VTE recurrence as PE reaches 4.1%
(95% CI : 3.4%-5.0%) in PE patients vs 1.1% (95% CI:
0.7%-1.8%) in DVT patients (pLogrank<0.0001) (Table 2).
During this period, the cumulative incidence rates of
first symptomatic VTE recurrence as DVT was 0.4%
(95% CI: 0.2%-0.9%) in PE patients vs 1.5% (95% CI:
1.0%-2.1%) in DVT patients. Predictive factors associated
with VTE recurrence as PE are presented in univariate
(Table 3) and multivariate analysis (Table 4). The risk of a
first VTE recurrence as PE was increased in patients
initially presenting with PE (OR= 2.04 (1.11-3.72), p<0.01),
as in patients with cancer (Table 4).
Major bleeding
Three months after the initial VTE event, 101 patients
(2.5%; 95% CI: 2.1-3.0) presented with a major bleeding
(Figure 2). Of these, 25 (25%) died of the bleeding event.
Major bleeding cumulative incidence at 3 months was
3.0% (95% CI: 2.4%-3.8%) in PE patients and 2.0% (95%
CI: 1.4%-2.8%) in DVT patients (pLogrank=0.06) (Table 2).
There was a trend toward an increased risk of major
bleeding in patients presenting with PE in univariate
analysis (Table 3), but it failed to reach significance
(OR= 1.46 (0.94-2.25) and was no more significant in
the multivariate analysis (Table 4). Only recent surgery
Table 1 Baseline characteristics of 4036 patients with
COPD according to initial VTE presentation
PE patients
(n=2452), %
DVT patients
(n=1584), %
p
Men 1579 (64.4) 1114 (70.3) <0.0001
Obesity (BMI > 30 kg/m2) 470 (19.2) 356 (22.5) 0.02
Age
Mean (SD) 73.4 (11.4) 72.0 (11.7) <0.0001
≥75 years 1332 (54.3) 727 (45.9) <0.0001
Cancer 535 (21.8) 353 (22.3) 0.73
Recent surgery 197 (8.0) 111 (7.0) 0.23
Previous VTE 383 (15.6) 290 (18.3) 0.02
Recent immobilization > 3 days 780 (31.8) 491 (31.0) 0.59
Recent immobilization is defined as an immobilization for non-surgical reason
≥4 days in the 2-month period prior to VTE diagnosis. Recent surgery is
defined as operation in the 2 month prior to VTE.
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Figure 1 PE recurrences according to initial presentation as DVT or PE.
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or immobilization were significantly associated with the
risk of major bleeding.
Fatal PE and all-cause death
Overall, 443 (cumulated incidence of 11.0%; 95% CI:
10.0-12.0) patients died during the 3-month study period
(Figure 3): 82 died of PE, 25 of bleeding, and 336 died
for other reasons (Table 5). The cumulative incidence of
death was higher in PE patients (12.5% (11.2%-13.8%))
compared to DVT patients (8.7% (7.4%-10.2%))
(pLogrank=0.0001)(Table 2).
At 3 months, fatal PE was retained for 82 patients
(2.0%; 95% CI: 1.6-2.5). The cumulative incidence rates
of fatal PE were 3.1% (95% CI: 2.5% - 3.9%) in PE
patients vs 0.4% (95% CI: 0.2 – 0.9%) in DVT patients
(pLogrank<0.0001) (Table 2). Predictive factors associated
with Fatal PE are presented in univariate (Table 3) and
multivariate analysis (Table 4). The risk of fatal PE
was increased in patients initially presenting with PE
(OR= 6.77 (6.77 (2.92-15.7), p<0.01), as in patients
with cancer or those recently immobilized (Table 4).
Discussion
To the best of our knowledge, the present study is the
largest clinical cohort focusing on patients presenting
with COPD and VTE. We found that COPD patients
presenting initially with PE concentrate the worse outcomes
and represent a therapeutic challenge, with more recurrent
VTE as PE and Fatal PE, but also a trend-toward an
increased risk of major bleeding.
In our study, 61% of COPD patients were objectively
diagnosed as having PE. We have recently pointed out
this modified clinical presentation [10], which may be
explained by the presence of already-known condition
leading to chronic dyspnea (say COPD) or by chronic
systemic inflammation. Another recent work describes
similar results in asthma, another pulmonary chronic
inflammatory disease [11].
COPD patients initially presenting with PE were more
likely to suffer recurrence as PE than DVT patients. The
impact of initial clinical presentation on the form of
recurrence is currently still under debate. For example,
PE was the form of recurrence in half of the patients
included in the EINSTEIN DVT study [12], while
patients with PE were shown to be at higher risk of
recurrence as PE than DVT patients in the general
settings [13]. Our 3.9-times increased risk is close to the
3-times increased risk of PE in PE patients compared to
DVT patients found in Baglin’s study. According to
recommendations regarding at-home treatment [14], we
may hypothesize that hospitalized DVT patients are at
higher risk of recurrence and closer to PE patients than
DVT patients managed at home. This argument is
reinforced by the way we classified patients as presenting
Table 2 Three-month cumulative incidence of study
outcomes according to initial VTE presentation
PE patients
(n=2452)
DVT patients
(n=1584)
p
First recurrent VTE as PEa 99 (4.1%) 17 (1.1%) <0.0001
All-cause deaths 305 (12.5%) 138(8.7%) 0.0002
Fatal PE* 76 (3.1%) 6 (0.4%) <0.0001
Major bleedings 70 (3.0%) 31 (2.0%) 0.08
a fatal or not.
* First recurrence or subsequent fatal PE.
Table 3 Univariable analysis for recurrent VTE, recurrent PE and fatal PE
Recurrent VTE Recurrent PE Fatal PE Major bleeding
Men 68 (76%) 42 (74%) 55 (66%) 65 (66%)
OR= 1.56 (0.96-2.53) OR= 1.41 (0.78-2.55) OR= 0.98 (0.62-1.56) OR= 0.99 (0.64-1.51)
Obesity (BMI > 30 kg/m2) 24 (35%) 12 (28%) 12 (18%) 22 (36%)
(N=2728) OR= 1.26 (0.76-2.09) OR= 0.89 (0.45-1.74) OR= 0.50 (0.27-0.95) OR= 1.30 (0.77-2.20)
Age ≥75 years 38 (42%) 21 (37%) 53 (64%) 63 (64%)
OR= 0.70 (0.46-1.07) OR= 0.56 (0.33-0.96) OR= 1.72 (1.10-2.71) OR= 1.76 (1.16-2.68)
Cancer 32 (36%) 19 (33%) 32 (39%) 25 (26%)
OR= 1.98 (1.28-3.07) OR= 1.78 (1.02-3.11) OR= 2.26 (1.44-3.54) OR= 1.22 (0.77-1.93)
Recent surgery 7 (7.8%) 3 (5.3%) 4 (4.8%) 13 (13%)
OR= 1.02 (0.47-2.23) OR= 0.67 (0.21-2.15) OR= 0.61 (0.22-1.67) OR= 1.90 (1.05-3.44)
Previous VTE 15 (17%) 7 (12%) 9 (11%) 18 (18%)
OR= 1.00 (0.57-1.75) OR= 0.70 (0.31-1.54) OR= 0.60 (0.30-1.21) OR= 1.12 (0.67-1.89)
Recent immobilization 26 (29%) 17 (30%) 44 (53%) 39 (39%)
OR= 0.96 (0.61-1.53) OR= 1.01 (0.57-1.79) OR= 2.75 (1.77-4.25) OR= 1.59 (1.06-2.40)
Initial presentation as PE 53 (59%) 43 (75%) 76 (92%) 68 (69%)
OR= 0.91 (0.60-1.39) OR= 1.97 (1.08-3.62) OR= 7.10 (3.27-15.4) OR= 1.46 (0.94-2.25)
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with PE. The presence of symptoms was a requisite.
However, some patients in the DVT group may also
have presented with an asymptomatic PE [15], leading
to shrinkage of the difference between the PE recurrence
risk of PE patients and DVT patients. In addition, as diag-
nosis of PE may be difficult in COPD patients since clinical
signs of COPD mimic PE [16,17], it is possible than some
recurrent PE were under-diagnosed in our study, in both
groups of patients.
The risk of major bleeding was 1.5 (95% CI of 0.9 to
2.2) higher in PE patients compared to DVT patients as
found in the whole VTE population from the RIETE
registry [18], despite the anticoagulation target does not
differ usually between DVT and PE patients [19]. The
non-statistically significant results in the subgroup of
COPD patients may be due to a lack of power.
The overall 3-month all-cause mortality in these
patients with concomitant COPD and VTE is estimated to
be 11.0%, three-time higher than in a recent randomized
control trial including stable COPD patients [20] and as
high as that one observed in COPD patients admitted in a
respiratory intensive care unit for a severe exacerbation
[21]. Besides the presence of PE in 60% of our patients,
this high mortality may be explained by the characteristics
of our population: elderly patients (51% over 75), 22% of
cancer. In this population at high risk of death, PE as the
presentation of the initial VTE increased the risk of death
by 1.5 (95% CI of 1.2 to 1.8). Despite significant thera-
peutic improvement in the management of VTE and
COPD, this result was already reported in the same pro-
portion more than twenty years ago (when none of the
COPD current treatments were available) in a small and
highly-selected group of COPD patients [22] and already
described in patients with VTE [23,24]. The association
between PE at presentation and a higher mortality raises
the possibility that some recurrent PE could have been
fatal, but classified as respiratory failure secondary to a
severe COPD exacerbation. Fatal PE may then have been
underdiagnosed. Of note, fatal PE represents the main
cause of death in patients, particularly in patients
presenting with PE. In COPD initially presenting with
PE the incidence of recurrent PE and major bleeding
was similar (69 vs. 70 events, respectively), but the
incidence of fatal, PE was 4 times higher than that of
Table 4 Multivariable analysis for recurrent VTE, recurrent PE, fatal PE and major bleeding
Recurrent VTE Recurrent PE Fatal PE Major bleeding
Cancer 2.11 (1.37-3.26) 1.91 (1.10-3.31) 3.43 (2.11-5.59) -
p-value=0.001 p-value=0.022 p-value=<0.001
Recent surgery - - - 2.41 (1.30-4.46)
p-value=0.005
Recent immobilization - - 3.53 (2.16-5.77) 1.88 (1.23-2.88)
p-value=<0.001 p-value=0.004
Initial presentation as PE - 2.04 (1.11-3.72) 6.77 (2.92-15.7) -
p-value=0.021 p-value=<0.001
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Figure 2 Major bleeding according to initial presentation as DVT or PE.
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fatal bleeding (76 vs. 17 deaths, respectively). In contrast,
in COPD patients initially presenting with DVT there were
17 PE recurrences and 31 major bleeding events, but the
incidences of fatal recurrent PE and fatal bleeding were
similar: 6 vs. 8 deaths. Thus, these observations suggest
that in COPD initially presenting with PE the major
concern should be recurrent (and potentially fatal) PE.
The main limitation in this study may be that the diagno-
sis of COPD in the RIETE registry may be questionable. No
functional tests were systematically performed to diagnose
COPD. This is unfortunately shared with the vast majority
of other observational studies [25-28]. For example, only
28% of patients included in a recent study [28] of acute
exacerbation of COPD had functional data. However,
there is little chance that patients have been misclas-
sified regarding their COPD status. The prevalence of
COPD in the RIETE registry is similar to prevalence
of COPD in general setting [29]. Moreover, COPD is
usually underdiagnosed [30], and so, if misclassifica-
tion exists, it should preferably be underdiagnosed.
Nevertheless, the record of the presence of COPD
was not different between PE and DVT patients, then
not leading to any measurement bias. Furthermore, it
could have been interesting to check whether the severity
of COPD is associated with the initial VTE clinical presen-
tation and whether it affects the association between PE
presentation and the 3-month outcomes. Unfortunately,
this variable was not available in the RIETE registry.
Conclusion
In conclusion, we found a significant higher risk of
recurrent VTE as PE and fatal PE in COPD patients
presenting with PE compared to those presenting
with DVT. As PE is the main cause of death during
the 3-month follow-up, there is a huge need for
treatment which would be more efficient in terms of
PE occurrence but also which would not induce an
increase in the bleeding risk, as there is also a trend
in a increased risk of bleeding. In this view, retrievable
vena cava filter [31], which protect the pulmonary
vascular bed without increasing the bleeding risk, deserves
further evaluations.
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Figure 3 Mortality according to initial presentation as DVT or PE.
Table 5 Reported causes of death, according to initial
VTE presentation
PE patients
(n=305)
DVT patients
(n=138)
Fatal pulmonary embolism 76 (24.9%) 6 (4.3%)
Respiratory insufficiency 55 (18.0%) 22 (15.9%)
Neoplasia 44 (14.4%) 37 (26.8%)
Infection 32 (10.5%) 14 (10.1%)
Fatal bleeding 17 (5.6%) 8 (5.8%)
Heart failure 10 (3.3%) 6 (4.4%)
Sudden death 6 (2.0%) 6 (4.4%)
Multi-organ failure 6 (2.0%) 5 (3.6%)
Myocardial infarction 5 (1.6%) 2 (1.5%)
Bowel occlusion 3 (1.0%) 1 (0.7%)
Liver insufficiency 2 (0.7%) 1 (0.7%)
Stroke 1 (0.3%) 2 (1.4%)
Terminal renal insufficiency 1 (0.3%) 2 (1.4%)
Critical limb ischemia 1 (0.3%) 0
Other 11 (3.6%) 2 (1.5%)0
Unknown 35 (11.5%) 24 (17.4%)
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